IRMA reports 1% five-year breast recurrence with partial irradiation but misses noninferiority

In 3,309 randomized patients, five-year ipsilateral breast recurrence was 1.0% with partial-breast irradiation versus 0.8% with whole-breast irradiation, without proven noninferiority.

KEY POINTS

  • IRMA (NCT01803958) was a multicenter, randomized phase III noninferiority trial conducted across 35 centers between 2007 and 2019. Eligible patients were aged ≥49 years and had invasive breast carcinoma with tumor diameter ≤3 cm, surgical margins ≥2 mm, and pN0–1 disease following breast-conserving surgery. 3,309 patients were randomized 1:1, including 1,652 assigned to accelerated partial-breast irradiation (APBI) and 1,657 to whole-breast irradiation (WBI). Neither patients nor investigators were blinded to treatment allocation.
  • The experimental treatment consisted of external-beam APBI delivering 38.5 Gy in ten twice-daily fractions. The primary endpoint was ipsilateral breast tumor recurrence (IBTR), assessed using a modified intention-to-treat population. The trial assumed a 4% five-year IBTR rate with WBI and was designed to exclude a clinically unacceptable increase in recurrence with APBI. The prespecified noninferiority margin was a hazard ratio of 1.5, with 90% statistical power.
  • The final primary-endpoint analysis included fewer patients than originally randomized. Of the 3,309 randomized participants, 84 were excluded from the modified intention-to-treat analysis, leaving 3,225 evaluable patients. Median follow-up reached 97.5 months, providing mature observation for the prespecified five-year endpoint. The supplied publication abstract does not specify the reasons for individual exclusions or provide a detailed breakdown of their potential influence on the primary analysis.
  • Five-year ipsilateral breast tumor recurrence was exceptionally low in both groups. Cumulative IBTR incidence was 1.0% with APBI (95% CI 0.6–1.6%) versus 0.8% with WBI (95% CI 0.5–1.4%). The rounded absolute difference was approximately 0.2 percentage points, substantially smaller than the event rate originally assumed during trial design. These findings demonstrate favorable observed local control with both approaches but do not alone establish statistical equivalence.
  • The trial did not demonstrate the prespecified noninferiority of APBI. The hazard ratio for APBI versus WBI was 1.18 (90% CI 0.63–2.20), with the upper confidence limit exceeding the noninferiority margin of 1.5. Therefore, although the point estimates were closely aligned, the available statistical precision could not exclude a relative increase in recurrence beyond the protocol-defined threshold. Failure to demonstrate noninferiority should not be interpreted as evidence that APBI was inferior, but neither can it support a formal claim of equivalent local control.
  • Interpretation should distinguish this specific twice-daily APBI regimen from other partial-breast techniques. The submitted material reports the primary oncological endpoint but does not contain the complete study manuscript, detailed treatment compliance data, toxicity tables, cosmetic outcomes, or subgroup results. The present findings therefore cannot independently establish comparative safety or patient-reported outcomes, and they should not be generalized automatically to contemporary once-daily external-beam APBI schedules or brachytherapy-based partial-breast irradiation.

CLINICAL TAKEAWAY

Five-year ipsilateral breast recurrence was approximately 1% with both accelerated partial-breast and whole-breast irradiation in appropriately selected patients with low-risk invasive breast cancer. However, the IRMA trial did not meet its prespecified noninferiority criterion, despite a very small observed absolute difference. Treatment selection should account for the specific twice-daily regimen, the statistical uncertainty, and previously reported toxicity and cosmetic outcomes.

SOURCE

Journal of Clinical Oncology

Browse more research Suggest a correction